Journal article

A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylated MGMT glioblastoma: the VERTU study

Hao-Wen Sim, Kerrie L McDonald, Zarnie Lwin, Elizabeth H Barnes, Mark Rosenthal, Matthew C Foote, Eng-Siew Koh, Michael Back, Helen Wheeler, Erik P Sulman, Michael E Buckland, Lauren Fisher, Robyn Leonard, Merryn Hall, David M Ashley, Sonia Yip, John Simes, Mustafa Khasraw

NEURO-ONCOLOGY | OXFORD UNIV PRESS INC | Published : 2021

Abstract

BACKGROUND: Temozolomide offers minimal benefit in patients with glioblastoma with unmethylated O6-methylguanine-DNA methyltransferase (MGMT) promoter status, hence, the need for novel therapies. This study evaluated whether veliparib, a brain-penetrant poly(ADP-ribose) polymerase (PARP) inhibitor, acts synergistically with radiation and temozolomide. METHODS: VERTU was a multicenter 2:1 randomized phase II trial in patients with newly diagnosed glioblastoma and MGMT-unmethylated promotor status. The experimental arm consisted of veliparib and radiotherapy, followed by adjuvant veliparib and temozolomide. The standard arm consisted of concurrent temozolomide and radiotherapy, followed by adj..

View full abstract